Microbix Biosystems Inc.
focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
The Company has reported a string of positive developments over the past several weeks, leading to a strong run-up in the share price. This Update Report focuses on the Company’s core virology business, while providing comments on: the impact of changes in the Canadian dollar; the LumiSort® funding; and the successful defence of the VIRUSMAX(TM) European patent.
eResearch rates Microbix shares as a Speculative Buy with an initial Target Price of $0.67 per share, while initiating secondary and tertiary Target Prices at $1.04 and $2.70 per share.
Read more in the detailed update here: Microbix Biosystems eResearch
posts all its reports and articles on its website and subscription is FREE. eResearch
is a primary source for professional investment research, focused on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.
eResearch: Bob Weir, CFA, Director of Research